A new method for measuring aerosol nebulizer output using radioactive tracers

A.A. Gatnash*, S.T. Chandler+, C.K. Connolly*

ABSTRACT: Reproducibility and comparability of bronchial challenge tests depends critically on accurate assessment of nebulizer output. Evaporation during nebulization means that simple weighing is inaccurate, overestimating the delivered dose of active ingredient. We wanted to quantify this effect in the context of intermittent nebulization, using a dosimeter as used in bronchial provocation tests.

Output of three types of nebulizer, from the MEFAR dosimeter, was measured by radioactive tracer, using a standard solution of technetium-99m-pertechnetate (1.5 kBq·mL⁻¹) in 4 mL of normal saline. The aerosol was impacted by suction onto a microfilter, and the radioactivity measured. Nebulizers were weighed before and after nebulization. Ratio of nebulized volume calculated from the radioactivity on the filter, to the total volume loss by weight, was expressed as nebulized ratio. The effect on output of two concentrations of methacholine, two tracers of different weights, and change in temperature, were assessed.

Nebulized ratio varied between 44.1–71.6%. Results were more consistent within the same type of nebulizer than between different makes. Neither changes in molar concentration nor molecular weight affected nebulizer output or nebulized ratio.

Mean nebulized ratio was 58.5%, showing that calibration by weighing, overestimates the delivered dose by a factor of approximately two. Measuring radioactivity eluted from a microfilter, onto which nebulized output had been impacted proved to be a satisfactory method of calibration.

Materials and methods

Dosimeter and nebulizers

The MEFAR Dosimeter MB3 (MEFAR, Brescia, Italy) was used. Characteristics and performance have been reported elsewhere [3]. The dosimeter pneumatic system delivered an output pressure of 88.2–99.3 kPa at an airflow of 0.37–0.42 L·s⁻¹. Three nebuliser models were used: 1) A1-A6 MEFAR, median diameter 2.0 µm; 2) G1-G2 Micro-Neb III (Lifecare Market Harborough, UK), median diameter 2.8 µm [4]; and 3) B1-B2 Sidestream (Medic-aid Bognor Regis, UK), median diameter 2.3 µm [4].

Inhalation time, pause time and the number of inhalations were kept constant. Each run consisted of 20 nebulizations of 1 s with an 8 s pause time.

Nebulizer solution

A standard solution (4 mL) was dispensed into each nebulizer. This consisted of technetium (Tc) 99m-pertechnetate (⁹⁹ᵐTcO₄⁻) (molecular weight (MW) 163) diluted in normal saline at a concentration of 1.5 kBq·mL⁻¹.
In order to assess the effect of the different molecular weight of the radioactive tracer on measured nebulizer performance, \(^{99m}\text{Tc}\)-disodium oxidronate (HDP; MW 223) and \(^{99m}\text{Tc}\)-diethylene triamine pentaacetic acid (DTPA; MW 492) were used as alternatives to the \(^{99m}\text{Tc}\)O\(_4\).

In the assessment of the effect of different drug concentrations on output, methacholine (MW 196) was added in two strengths (0.003 mg·mL\(^{-1}\) and 1.6 mg·mL\(^{-1}\)) to the standard \(^{99m}\text{Tc}\)O\(_4\) solution.

### Aerosol collection

The nebulizers were connected to a t-piece leading directly to a filter, without interposition of face-masks or mouthpieces, as shown in figure 1. The aerosol was impacted onto the microfilter (Whatman glassfibre (GF/A), Whatman Maidstone, UK) connected to a suction machine rated at 10–14 L·min\(^{-1}\) \([2]\), which was adequate for total impact of output radioactivity with no breakthrough. This was confirmed by a second filter connected in series with the first, which was checked for the presence of any radioactivity.

### System loss detection

The whole system was imaged in front of a gamma camera (IGE Starport 400AT IGE Medical, Radlett, UK) before, during and after the nebulization process, using a higher activity of \(^{99m}\text{Tc}\)O\(_4\) (10 MBq·mL\(^{-1}\)), to establish the distribution of radioactivity within the system.

### Temperature

The temperature was measured by a digital thermometer after each 20 nebulizations.

**Output measurements**

**Weight output.** Each nebulizer was weighed on a precision scale (Oertling R42; London, UK) before and after each run of 20 nebulizations. Weight difference (mean of three readings) is expressed as µg·nebulization\(^{-1}\).

**Isotopic output.** The filter was changed after each run of 20 nebulizations. Radioactivity in the filter paper was eluted in a counting tube by adding a fixed volume of 5% ethylenediamine tetraacetic acid (EDTA) solution to provide constant measurement geometry. Each tube was then counted in a gamma counter (Canberra Packard 5550; Pangbourne, UK) against a fixed volume of the standard solution. The activity was corrected for time and decay and expressed as counts·min\(^{-1}\). The sensitivity of the gamma counter for \(^{99m}\text{Tc}\) is 60%, giving \(6 \times 10^4\) counts·min\(^{-1}\)·kBq\(^{-1}\).

The range of measurements obtained in 20 nebulizations gives 3,600–15,000 counts·min\(^{-1}\) for the filters, against a background of 40 counts·min\(^{-1}\). A 5 min count time gives an SD for the individual measurements of 0.4–1.3%. The overall theoretical precision of the measurement technique is 5.2%. The samples were counted only once due to radioactive decay. Output (µL·nebulization\(^{-1}\)) was calculated from the activity in the filter paper eluate against activity of the standard.

**Nebulized ratio (NR).** The proportion (%) of output actually nebulized was calculated from the following formula:

\[
100 \times \text{isotopic output/weight output}
\]

**Concentration change.** Forty nebulizations were performed with three different nebulizers. Two samples (1 mL each) were withdrawn from the residual nebulizer solution and counted against the standard. Percentage change in concentration was calculated from the formula:

\[
100 \times (\text{final activity} - \text{standard activity})/\text{standard activity}
\]

The process was repeated three times for nebulizers A1 and B1, and twice for nebulizer G1.

**Effect of different materials.** The effect of different radioactive tracers with a higher molecular weight on measured nebulizer output was assessed, using \(^{99m}\text{Tc}\)-HDP and \(^{99m}\text{Tc}\)-DTPA. Similarly, aerosol output was measured using \(^{99m}\text{Tc}\)O\(_4\) but with methacholine added to the nebulizer at low (0.003 mg·mL\(^{-1}\)) and high (1.6 mg·mL\(^{-1}\)) concentrations.

**Reproducibility.** The accuracy of the method in measuring the output from individual nebulizations was assessed by performing 10×1 s nebulizations and changing the filter after each nebulization. This was repeated for an individual nebulizer (B1) on four separate occasions.

### Results

**System loss**

There was no radioactivity on the second filter in the series. No loss through the air input tube was demonstrated by imaging during nebulization. The activity within
the system, other than in the nebulizer chamber or on the first filter, amounted to <2% of the total activity. The gamma camera image of the system of the MEFAR nebulizer, both before and after removal of the nebulizer and filter, is shown in figure 2.

Temperature change

The temperature changes with sequential nebulizations are shown in figure 3. The mean temperature in the laboratory was 23°C. Relative humidity was not measured at the time of each run, but varied between 40–50%. The fall was 0.4°C at 20 and 0.75°C at 40 nebulizations, and did not fall >2.4°C below the initial temperature, with stable readings from 140–200 nebulizations.

Output measurements

The weight loss and isotopic output for the different models of nebulizers are shown in table 1. These results summarize all the values obtained, including those made with different radioactive tracers and methacholine concentrations.

Nebulized ratio (NR) varied between 44.1–71.6% (mean 58.5%) according to the nebulizer used. One MEFAR nebulizer gave a consistently lower NR than the other five, with the other two pairs of nebulizers giving consistent results for the same type.

Reproducibility. The results for four repeat measurements of output for 10 separate 1 s nebulizations were: 4.80 (±0.17), 4.72 (0.18), 4.73 (0.19) and 4.61 (0.10) µL. These results suggest that a high degree of consistency is possible with this technique and hence variations in measured values are likely to be due to individual nebulizer characteristics.

Change in concentration. The changes in concentration are shown in figure 4. The range was 0.8–3.3% (mean 1.67%). This is consistent with the deficit in NR being due to evaporation, after allowing for experimental error and the scatter of small quantities of solution within the system.

Effect of different materials. The effect of different materials on isotopic output are shown in table 2. Changes in the

<table>
<thead>
<tr>
<th>Neb No.</th>
<th>No. of runs</th>
<th>µL·neb⁻¹ isotope</th>
<th>µg·neb⁻¹ weight</th>
<th>Nebulized ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1</td>
<td>8</td>
<td>7.1 (0.7)</td>
<td>11.2 (0.7)</td>
<td>63.2 (9.8)</td>
</tr>
<tr>
<td>A2</td>
<td>16</td>
<td>6.0 (0.8)</td>
<td>9.2 (0.6)</td>
<td>65.0 (5.6)</td>
</tr>
<tr>
<td>A3</td>
<td>10</td>
<td>5.1 (1.0)</td>
<td>8.4 (0.5)</td>
<td>61.1 (15.3)</td>
</tr>
<tr>
<td>A4</td>
<td>12</td>
<td>8.3 (0.9)</td>
<td>11.9 (1.8)</td>
<td>70.9 (12.3)</td>
</tr>
<tr>
<td>A5</td>
<td>12</td>
<td>5.1 (0.2)</td>
<td>10.9 (0.9)</td>
<td>46.8 (4.6)</td>
</tr>
<tr>
<td>A6</td>
<td>8</td>
<td>8.7 (0.4)</td>
<td>12.2 (0.6)</td>
<td>71.6 (3.7)</td>
</tr>
<tr>
<td>G1</td>
<td>16</td>
<td>2.4 (0.2)</td>
<td>4.0 (0.2)</td>
<td>59.7 (4.7)</td>
</tr>
<tr>
<td>G2</td>
<td>4</td>
<td>2.1 (0.1)</td>
<td>3.9 (0.4)</td>
<td>54.0 (2.2)</td>
</tr>
<tr>
<td>B1</td>
<td>16</td>
<td>2.0 (0.4)</td>
<td>4.1 (0.5)</td>
<td>48.3 (5.9)</td>
</tr>
<tr>
<td>B2</td>
<td>4</td>
<td>2.1 (0.2)</td>
<td>4.7 (0.1)</td>
<td>44.1 (5.2)</td>
</tr>
</tbody>
</table>

Data are presented as means (±). neb: nebulizer; A: MEFAR; B: Sidestream; G: Micro-Neb III.
molar concentration of methacholine or molecular weight of the tracer did not give any significant difference in output from the results obtained with the standard solution of $^{99m}$TcO$_2$ (t-test, p=0.5).

### Discussion

There is potential for great variation between bronchial challenge tests when performed in different centres. This makes the comparison of results difficult, particularly in large, multicentre epidemiological studies, unless standardization is consistent. Potential causes of variation are the methodology used; in particular, tidal breathing or dosimeter method, nebulizer output volume, particle size, and the ventilatory condition and pattern of breathing of the subject. Of these factors, the actual volume nebulized is probably the most important. Ryan et al. [1] reported that nebulizer output volume, but not particle size in the range 1.3–3.6 µm, altered the response in bronchial challenge tests.

Our results show that the assessment of nebulizer output by weight loss considerably overestimates the aerosol delivered to the patient. This error may be as high as 50–60% in commercially available nebulizers. We confirm the findings of Dennis et al. [2], who used a chemical tracer to measure actual aerosol output. The discrepancy between weight loss and direct measurement of aerosol has also previously been shown by Smye and coworkers [5, 6]. O’Callaghan et al. [7] used a spectrophotometric method to assess drug output from nebulizers, but this method requires specialized equipment and may not be sensitive enough for smaller dosimeter doses.

Phillips et al. [8] studied the radioaerosol delivery systems used for lung ventilation imaging. However, such techniques measure high levels of radioactivity generated from relatively long periods of continuous nebulization and would not be sufficiently sensitive to measure the relatively small output from intermittent nebulization used in challenge testing. In addition, these methods require the assessment of particle size distribution using a cascade impactor. Such equipment is not commonly available in nuclear medicine departments.

In contrast, the technique we have described can measure the output from a single nebulization using relatively low levels of radioactivity and using standard equipment. Although care is needed in the handling of any radioactive materials, the amount of radioactivity used is low and the hazard is negligible.

We did not explore the effects of the change in temperature on nebulizer output. König and coworkers [9] showed an increase in mean output by approximately 23% when the temperature was increased from 19 to 24°C. Although we did sometimes perform two runs of 20 nebulizations in rapid sequence, the findings of König and coworkers [9] suggest that the change of 0.75°C demonstrated in this study over 40 consecutive nebulizations is unlikely to have had a relevant effect on evaporation.

Nebulization itself is not associated with change in concentration of a solute, but evaporation would be expected to produce an increase in the concentration of the solution. The small change in concentration demonstrated was anticipated by a simple calculation from the observed nebulized ratio, or using the model of Smye et al. [6]. Using a simple ionic solution, Schon and Kramar [10] demonstrated an increase in osmolality from 282 to 432 mmol·kg$^{-1}$ as the solution in the nebulizer chamber approached exhaustion. We have confirmed that this is not a major problem at the beginning of nebulization. As long as the nebulizer is refilled for each experiment, the error arising from the change in concentration of the active constituents is negligible, certainly within the range of concentrations used in the clinical situation.

Although particle size has been found to be less important than total nebulized output in determining variation in the results of aerosol provocation tests [1], it is a potentially confounding variable. Although we have not addressed this point, published results would suggest that drug concentration has little effect on particle size [11]. We have shown that a change in methacholine concentration from 0.003 to 1.6 mg·mL$^{-1}$, covering the range of concentrations used in our aerosol provocation tests, produced no change in nebulizer output.

Similarly, the output was independent of the molecular weight of the tracers used. These results were obtained with actual concentrations used in our bronchial provocation tests. Results obtained under different conditions, such as continuous nebulization or until the nebulizer runs dry, may well give differing results.

In therapy, continuous nebulization is used, where the dose actually delivered is often less critical than in bronchial provocation tests. Nevertheless, where the clinical dose is important, nebulizer calibration should include estimates of NR during continuous nebulization. This might be of particular relevance where a critical dose of inhaled corticosteroids is required, or with the more viscous solutions produced by antibiotics. Our results cannot be applied directly to these situations. The results do, however, emphasize the need to test the combination of delivery device and nebulizer in conditions as close as possible to those of actual usage, particularly as others have suggested that output may be modified by addition of the β-agonist fenoterol to the radioactive tracer. However, output

### Table 2. Effect of different materials on isotopic output (µL·neb$^{-1}$)

<table>
<thead>
<tr>
<th>Nebulizer</th>
<th>$^{99m}$TcO$_2$</th>
<th>Methacholine concentration*</th>
<th>HDP</th>
<th>DTPA</th>
</tr>
</thead>
<tbody>
<tr>
<td>A2</td>
<td>5.9 (0.1)</td>
<td>5.9 (0.2)</td>
<td>5.7 (0.1)</td>
<td>5.8 (0.2)</td>
</tr>
<tr>
<td>G1</td>
<td>2.3 (0.1)</td>
<td>2.8 (0.2)</td>
<td>2.6 (0.7)</td>
<td>2.4 (0.6)</td>
</tr>
<tr>
<td>B1</td>
<td>1.9 (0.3)</td>
<td>2.1 (0.1)</td>
<td>2.0*</td>
<td>2.1 (0.6)</td>
</tr>
<tr>
<td>Normalized for all 3</td>
<td>1.00 (0.09)</td>
<td>1.05 (0.25)</td>
<td>1.04 (0.07)</td>
<td>1.07 (0.13)</td>
</tr>
</tbody>
</table>

Results are presented as mean (SD). A2: MEFAR; G1: Sidestream; B1: Micro-Neb III; $^{99m}$TcO$_2$: $^{99m}$Tc-pertechnetate (molecular weight (MW) 163); HDP: $^{99m}$Tc-disodium oxidronate (MW 223); DTPA: $^{99m}$Tc-diethylene triamine pentaacetic acid (MW 492). *: methacholine (MW 196) at low (0.003 mg·mL$^{-1}$) and high (1.6 mg·mL$^{-1}$) concentrations; *: only one sample obtained.
measurements performed with either drug alone or only radioactive tracer, were comparable [12].

Differences in interactions between the nebulizer’s plastic surfaces and other radioisotopes not tested here might also cause differences between apparently similar nebulizers or batches. It is, therefore essential that the actual nebulizer to be used should be tested when doses are critical. The method described here represents a simple technique using standard equipment and materials available in many hospitals, and produces consistent results. It has been demonstrated that the dose delivered by the nebulizer may be overestimated by between approximately 30–60% if calibration is achieved by simple weighing.

References